Fetalix featured in Revista Sábado on emerging approaches to pain treatment
Advances in regenerative medicine are opening new possibilities for the treatment of chronic conditions that have traditionally relied on symptom management. As innovative therapeutic strategies continue to emerge, communicating their potential to the wider public is essential.
Fetalix Secures Patent for Its Fetal-Inspired Regenerative Biomaterial
Fetalix has been granted a patent protecting its regenerative biomaterial technology for the treatment of intervertebral disc degeneration and associated low back pain. The patent represents an important milestone in the company’s development, securing intellectual property rights for key aspects of its product and supporting its continued advancement toward clinical application.
Fetalix contributes to the discussion on translating research into innovation at TERMIS-EU 2026
The journey from academic research to market-ready healthcare solutions is shaped by more than scientific discovery. The successful translation of research into healthcare solutions depends on entrepreneurship, strategic development, and collaboration across academia, industry, and the investment ecosystem.
